The YY1-CDK9 transcriptional complex in GBM cells promotes Treg infiltration, inhibits RNA methylation-dependent interferon responses, and reduces the efficacy of immune checkpoint inhibitor therapy in GBM (77), highlighting how transcription factors and epigenetic modifications cooperate to impart immunomodulatory function in GBM cells. Here, CDK9 is linked to glioblastoma.